Acacia Pharma Group
Manufacturing · Indiana, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
8440 Allison Pointe Blvd Ste 100, Indian...Phone Number
(317) 505-1280Website
www.acaciapharma.comRevenue
$40.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Acacia Pharma Group
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.Explore more
Acacia Pharma Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acacia Pharma Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Acacia Pharma Group, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Acacia Pharma Group launches new products
Congratulate Masked Content for being promoted to Masked Content at Acacia Pharma Group
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Acacia Pharma Group recently announced quarterly report
Check out if Acacia Pharma Group is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Acacia Pharma Group has new funding data
Check if Acacia Pharma Group has recently received funding, and reach out quickly before it becomes old news!
Click to see if Acacia Pharma Group had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Acacia Pharma Group as Masked Content
Find 2 more new buyers
Compare Similar Companies to Acacia Pharma Group
Compare insights from companies similar to Acacia Pharma Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Acacia Pharma Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acacia Pharma Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acacia Pharma Group.
Acacia Pharma Group financials insights
Gather financial insights about Acacia Pharma Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$10M
2013
Series B
$23.5M
Acacia Pharma Group Tech Stack
A closer look at the technologies used by Acacia Pharma Group
Most Recent Scoops
Facilities Relocation / Expansion
Acacia Pharma Group is planning to move offices in September 2025. The move will impact employees at the existing office located at 8440 Allison Pointe Blvd 100, Indianapolis, IN.
Facilities Relocation/Expansion
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Left Company
Executive Move
Acacia Pharma Group News & Media
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire issued share capital of Acacia Pharma Group plc (“Acacia Pharma”) (EURONEXT: ACPH) by way of a scheme of arrangement under Part 26 of the United Kingdom’s Companies Act 2006 (the “Transaction”).Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022
Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acacia Pharma Group
Sign Up For FreeTo access detailed company insights
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomi... Read More
